{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:12:36Z","timestamp":1788502356066,"version":"build-2803163510"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal choice of chemotherapy regimen for resectable colorectal liver metastases (CRLM) is still undetermined. The study aimed to estimate the impact of perioperative or adjuvant chemotherapy on disease-free survival (DFS), and explore the underlying mechanisms which influence chemotherapy efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eight hundred twenty-two patients undergoing curative resection of CRLM were retrospectively collected from May 2018 to December 2023. Treatment effects between perioperative and adjuvant chemotherapy were compared in full subgroup analyses by Kaplan\u2013Meier and Cox proportional hazards methods. Single-cell RNA sequencing and tumor derived organoids were used to explore the molecular mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After propensity score matching, 630 patients were enrolled with ratio 1:1 in adjuvant and perioperative chemotherapy group. The median DFS in adjuvant and perioperative group was comparable with 28 and 32.5 months, respectively (HR\u00a0=\u00a00.99,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.945). Perioperative chemotherapy was associated with improved DFS (25 vs. 13 months,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.039) in patients with a clinical risk score (CRS) of 5. Notably, within the high-risk CRS 4-5 population receiving perioperative chemotherapy, patients with chronic hepatitis B (CHB) had significantly worse DFS (HR\u00a0=\u00a04.31, 95% CI 1.93\u20139.64;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001). Single-cell analyses revealed TSPAN8\n                      <jats:sup>+<\/jats:sup>\n                      stem-like epithelial cells were enriched in sample with CHB. TSPAN8 knockdown sensitized colorectal cancer cells to 5-fluorouracil, and anti-TSPAN8 antibody showed synergistic efficacy with 5-fluorouracil in patient-derived liver metastasis organoids. In addition, the enhanced SPP1-CD44 signaling between TSPAN8\n                      <jats:sup>+<\/jats:sup>\n                      epithelial cells and SPP1\n                      <jats:sup>+<\/jats:sup>\n                      macrophages also contributed to 5-fluorouracil resistance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Higher CRS identify a subgroup of CRLM patients who may derive greater benefit from perioperative chemotherapy. HBV-related serological profiles is a potential predictor of chemotherapy resistance. The exploratory findings warrants further validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1914602","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:29:08Z","timestamp":1788499748000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronic hepatitis B and perioperative chemotherapy efficacy in colorectal liver metastases: an exploratory analysis of clinical and mechanistic evidence"],"prefix":"10.3389","volume":"17","author":[{"given":"Chun-Liang","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Colorectal Surgery, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-You","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Bo","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"San-Jun","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Jie","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0b013e3181b4539b","article-title":"Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients","volume":"250","author":"de Jong","year":"2009","journal-title":"Ann Surg"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq222","article-title":"Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment","volume":"21","author":"Van Cutsem","year":"2010","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(13)70447-9","article-title":"Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial","volume":"14","author":"Nordlinger","year":"2013","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-017-1101-6","article-title":"Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer","volume":"23","author":"Watanabe","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0029","article-title":"Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Benson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2015.04.012","article-title":"The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator","volume":"41","author":"Ayez","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3182356236","article-title":"Chemotherapy before liver resection of colorectal metastases: friend or foe","volume":"255","author":"Lehmann","year":"2012","journal-title":"Ann Surg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-012-2438-8","article-title":"Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis","volume":"19","author":"Robinson","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases","volume":"230","author":"Fong","year":"1999","journal-title":"Ann Surg"},{"key":"B11","article-title":"ClinicalTrials.gov","year":""},{"key":"B12","year":""},{"key":"B13","article-title":"Randomized phase III trial of surgery followed by mFOLFOX6 as adjuvant chemotherapy versus peri-operative mFOLFOX6 plus cetuximab for KRAS wild type resectable liver metastases of colorectal cancer","author":"Hasegawa","year":"2012"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/bjs5.50174","article-title":"Multicentre study of perioperative versus adjuvant chemotherapy for resectable colorectal liver metastases","volume":"3","author":"Allard","year":"2019","journal-title":"BJS Open"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030613","article-title":"Upfront Surgery versus Neoadjuvant Perioperative Chemotherapy for Resectable Colorectal Liver Metastases: A Machine-Learning Decision Tree to Identify the Best Potential Candidates under a Parenchyma-Sparing Policy","volume":"15","author":"Famularo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.surg.2009.02.017","article-title":"One-stage ultrasonographically guided hepatectomy for multiple bilobar colorectal metastases: a feasible and effective alternative to the 2-stage approach","volume":"146","author":"Torzilli","year":"2009","journal-title":"Surgery"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2580","article-title":"A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study","volume":"26","author":"Austin","year":"2007","journal-title":"Stat Med"},{"key":"B18","volume-title":"Propensity Score Matching in SPSS","author":"Thoemmes","year":"2012"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-23-0193","article-title":"Cross-talk between myeloid and B cells shapes the distinct microenvironments of primary and secondary liver cancer","volume":"83","author":"Chen","year":"2023","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2026.101414","article-title":"Functional precision oncology platform of BRAF(V600E)-mutated colorectal cancer organoids predicts therapy response and reveals RNF43-mediated immunogenicity","volume":"87","author":"Mo","year":"2026","journal-title":"Drug Resist Update"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2021.07.024","article-title":"Efficacy of perioperative chemotherapy in resected colorectal liver metastasis: A systematic review and meta-analysis","volume":"47","author":"Bosma","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.06.8353","article-title":"Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial","volume":"24","author":"Portier","year":"2006","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.17.3781","article-title":"Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials","volume":"26","author":"Mitry","year":"2008","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj5705","article-title":"TSPAN8(+) myofibroblastic cancer-associated fibroblasts promote chemoresistance in patients with breast cancer","volume":"16","author":"Fan","year":"2024","journal-title":"Sci Transl Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.mcr-21-0565","article-title":"Distinct transcriptional programs in ascitic and solid cancer cells induce different responses to chemotherapy in high-grade serous ovarian cancer","volume":"20","author":"Loret","year":"2022","journal-title":"Mol Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07172-7","article-title":"Comprehensive genetic search to clarify the molecular mechanism of drug resistance identifies ASCL2-LEF1\/TSPAN8 axis in colorectal cancer","volume":"26","author":"Tanaka","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/biom10030388","article-title":"TSPAN8 as a novel emerging therapeutic target in cancer for monoclonal antibody therapy","volume":"10","author":"Heo","year":"2020","journal-title":"Biomolecules"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02381-z","article-title":"Integrating single cell- and spatial- resolved transcriptomics unravels the inter-tumor heterogeneity and immunosuppressive landscape in HBV- and Clonorchis sinensis-associated hepatocellular carcinoma","volume":"25","author":"Chen","year":"2026","journal-title":"Mol Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","article-title":"Landscape and dynamics of single immune cells in hepatocellular carcinoma","volume":"179","author":"Zhang","year":"2019","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","article-title":"Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer","volume":"181","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084247","article-title":"Macrophages cytokine spp1 increases growth of prostate intraepithelial neoplasia to promote prostate tumor progression","volume":"23","author":"Messex","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13578-024-01218-4","article-title":"Revealing the role of SPP1(+) macrophages in glioma prognosis and therapeutic targeting by investigating tumor-associated macrophage landscape in grade 2 and 3 gliomas","volume":"14","author":"Tang","year":"2024","journal-title":"Cell Biosci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082250","article-title":"The significance of SPP1 in lung cancers and its impact as a marker for protumor tumor-associated macrophages","volume":"15","author":"Matsubara","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3516973","article-title":"The pancreatic cancer-initiating cell marker CD44v6 affects transcription, translation, and signaling: consequences for exosome composition and delivery","volume":"2019","author":"Sun","year":"2019","journal-title":"J Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1118","article-title":"Effect of concomitant positive hepatitis B surface antigen on the risk of liver metastasis: A retrospective clinical study of 4033 consecutive cases of newly diagnosed colorectal cancer","volume":"66","author":"Huo","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1914602\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:29:10Z","timestamp":1788499750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1914602\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2026.1914602"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1914602","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1914602"}}